| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/19/2002 | US20020132778 Modulating angiogenesis |
| 09/19/2002 | US20020132777 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 09/19/2002 | US20020132776 Inhibitors of transglutaminase |
| 09/19/2002 | US20020132775 Human potassium channel 1 and 2 proteins |
| 09/19/2002 | US20020132774 Neuropilin antagonist that binds neuropilin and has VEGF antagonist activity as determined by the human umbilical vein endothelial cell proliferation assay using VEGF165; treatment of metastatic cancer, and angiogenic diseases. |
| 09/19/2002 | US20020132773 Methods for reducing fat by administration of adiponectin |
| 09/19/2002 | US20020132772 Administered to delay the clinical onset of diabetes, to reduce the occurrence of beta cell destruction, to provide a regulating effect on spleen T cells, or to reduce the likelihood of the occurrence of clinical diabetes |
| 09/19/2002 | US20020132770 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| 09/19/2002 | US20020132769 Comprising a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain; using molecule to treat a disease, such as cancer, with adenoviral gene therapy; side effect reduction |
| 09/19/2002 | US20020132768 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/19/2002 | US20020132767 Nucleic acids, proteins, and antibodies |
| 09/19/2002 | US20020132765 Powerful activity when administered orally and by injection so that they can be used in a hospital environment via injection, followed by an oral ambulatory treatment |
| 09/19/2002 | US20020132764 Cyclosporin; mycophenolic acid or its salt as an immunosuppressor; and rapamycin or a derivative |
| 09/19/2002 | US20020132763 Deuterated cyclosporine analogs and their use as immunomodulating agents |
| 09/19/2002 | US20020132762 Contacting the antibiotic with a divalent metal ion and an organic solvent, to extract the lipopeptide antibiotic into the solvent; and contacting the extract of the lipopeptide antibiotic with acid. |
| 09/19/2002 | US20020132761 Glycoprotein matrix bound to a biologically active ingredient, especially a vitamin, mineral, or L-Carnitine base; optionally contains a bioflavonoid, a yeast and/or a bacterium |
| 09/19/2002 | US20020132760 First insulin species and the second insulin species form a heterodimeric complex that is more stable than either homodimeric complex |
| 09/19/2002 | US20020132759 Remedies for diseases caused by insulin resistance |
| 09/19/2002 | US20020132757 Formulations for administering calcitonin and processes for preparing the same |
| 09/19/2002 | US20020132753 Nucleic acids, proteins, and antibodies |
| 09/19/2002 | US20020132334 Nucleotide sequences coding preferential polypeptide for use in the treatment of tumors and nervous system disorders |
| 09/19/2002 | US20020132330 Polypeptide for use in the treatment, prevention and diagnosis of inflammation, cell proliferation and apoptosis |
| 09/19/2002 | US20020132329 ELL2, a new member of an ELL family of RNA polymerase II elongation factors |
| 09/19/2002 | US20020132324 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/19/2002 | US20020132322 For use in therapy |
| 09/19/2002 | US20020132321 14790, Novel protein kinase molecule and uses therefor |
| 09/19/2002 | US20020132317 Polypeptide for use in the treatment and diagnosis of cancer, diabetes, hematopoeitic and nervous system disorders |
| 09/19/2002 | US20020132306 Premature antihemopliic factor; for use in the treatment of blood disorders |
| 09/19/2002 | US20020132304 Nucleotide sequences coding preferential protein for use in the treatment and diagnosis of digestive, nonimmune defense, endocrine or immune system disorders |
| 09/19/2002 | US20020132303 Nucleotide sequences coding transport protein for use in the treatment of nervous system, cardiovascular, cellular proliferative and/or differentiative, immune, inflammatory, hematopoietic, pain or metabolic disorders |
| 09/19/2002 | US20020132301 Nucleotide sequences coding transport protein for use in the treatment of vision defcets, liver, cardiovascular, nervous system and cell proliferation disorders |
| 09/19/2002 | US20020132300 Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases |
| 09/19/2002 | US20020132298 Nucleotide sequences coding polypeptide for use in the treatment of muscular and nervous sytem disosrders |
| 09/19/2002 | US20020132296 Human Ste20-like stress activated serine/threonine kinase |
| 09/19/2002 | US20020132293 Mammalian neuralized family transcriptional regulators and uses therefor |
| 09/19/2002 | US20020132291 Polypeptide for use in human therapeutics and diagnostics; for use in treating tumors |
| 09/19/2002 | US20020132279 Adjusting glucose concentration in humans; obtain carbohydrate sufficient to adjust blood glucose, ingest, monitor blood glucose concentration |
| 09/19/2002 | US20020132275 Methods for detecting the efficacy of anticancer treatments |
| 09/19/2002 | US20020132269 For use in diagnosis therapy |
| 09/19/2002 | US20020132253 Nucleotide sequences coding membrane protein for use in diagnosis and treatment of athersclerosis, infections, arthritis, cancer, kidney and nervous system disorders |
| 09/19/2002 | US20020132252 Nucleotide sequences coding membrane protein for use in the diagnosis and treatment of infections, arthritis, nervous system and kidney disorders, cancer and atherosclerosis |
| 09/19/2002 | US20020132250 EGF motif protein, EGFL6 materials and methods |
| 09/19/2002 | US20020132240 Nucleotide sequences coding membrane proteins for use in treatment of cancer, infections, cardiavascular, nervous system, skin and kidney disorders |
| 09/19/2002 | US20020132238 Progesterone receptor complex p23-like protein |
| 09/19/2002 | US20020132237 Detecting ovarian cancer humans; obtain sample, incubate with preferential oligonucleotides, monitor hybridization, compare to control, evaluate for cancer |
| 09/19/2002 | US20020132229 Detecting modulators of viral propagation; obtain cell, transform with expression vector containing modulator, incubate cell with virus, recover propagating cells |
| 09/19/2002 | US20020132225 Compositions and methods for prolonging survival of chilled platelets |
| 09/19/2002 | US20020132224 CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis |
| 09/19/2002 | US20020132030 Edible microbiocide of .05-1.0% alkyl paraben, and .1-.2% benzoic and sorbic acids salts |
| 09/19/2002 | US20020132017 Composition and method for preserving progenitor cells |
| 09/19/2002 | US20020132016 Extracting a fraction with an optical absorbance of 210-250 nm; inhibiting the growth of endothelial cells and vascularization; anticancer agents |
| 09/19/2002 | US20020132011 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| 09/19/2002 | US20020132001 Delayed-release formulation of aldosterone antagonist drug which when orally administered 6-12 hours prior to acrophase provides profile of plasma drug concentration corresponding to diurnal cycle of plasma aldosterone concentration |
| 09/19/2002 | US20020131983 Method for inducing an immunological response in a host by administering to the host at least one antigen and a lipoprotein |
| 09/19/2002 | US20020131971 Compositions and methods for the therapy and diagnosis of colon cancer |
| 09/19/2002 | US20020131970 Fibrinogen homolog capable of binding to endothelial cells in an arginine-glycine-aspartic acid (RGD)-independent manner that inhibits fibrinogen binding to endothelial cells; inhibiting tumor metastasis |
| 09/19/2002 | US20020131968 An Immunoglobulin G (IgG) antibody with binding affinity for the CD3 antigen in which the heavy chain has a variable region framework together with specified complementary determining region (CDR); immunosuppressant, treating cancer |
| 09/19/2002 | US20020131967 Such as melphalan and an anti-interleukin-6 receptor antibody, administering in synergistic amounts |
| 09/19/2002 | US20020131966 Anti-idiotypic antibodies of vascular endothelial growth factor and use thereof as drugs |
| 09/19/2002 | US20020131965 Conjugate of a bioactive agent covalently attached to a transport polymer, having guanidino or amidino side chains, such as an arginine-containing polypeptide |
| 09/19/2002 | US20020131964 Compositions and methods for modulating muscle cell and tissue contractility |
| 09/19/2002 | US20020131963 Methods and compositions for treating type i diabetes using glutamic acid decarboxylase |
| 09/19/2002 | US20020131961 Gene transfer of Bcl2 and a selected transgene to cells; Bcl2 protects cells which express it from apoptosis so they can be selected by administering an apoptotic agent |
| 09/19/2002 | US20020131959 Contacting an organ, tissue or cells with transforming growth factor beta 1 (TGF beta 1) |
| 09/19/2002 | US20020131955 Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| 09/19/2002 | US20020131954 Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| 09/19/2002 | US20020131953 In situ langerhans cell vaccine |
| 09/19/2002 | US20020131951 Biodegradable poly(beta-amino esters) and uses thereof |
| 09/19/2002 | CA2702192A1 Igf antagonist peptides |
| 09/19/2002 | CA2473979A1 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | CA2470152A1 Transfection complexes comprising a novel peptide as cell surface receptor binding component |
| 09/19/2002 | CA2455413A1 Mammalian neuralized family transcriptional regulators and uses therefor |
| 09/19/2002 | CA2454959A1 Mva expressing modified hiv envelope, gag, and pol genes |
| 09/19/2002 | CA2441495A1 Proteins associated with cell growth, differentiation, and death |
| 09/19/2002 | CA2441454A1 Recombinant adeno-associated virus-mediated gene transfer via retroductal infusion of virions |
| 09/19/2002 | CA2441434A1 Remedies for nerve damages |
| 09/19/2002 | CA2441210A1 Novel peptide ligands of leukocyte integrins |
| 09/19/2002 | CA2441082A1 Steap-related protein |
| 09/19/2002 | CA2441006A1 Methods and materials relating to fibulin-like polypeptides and polynucleotides |
| 09/19/2002 | CA2440974A1 High affinity integrin polypeptides and uses thereof |
| 09/19/2002 | CA2440773A1 Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| 09/19/2002 | CA2440658A1 Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer |
| 09/19/2002 | CA2440618A1 Immunoglobulin superfamily proteins |
| 09/19/2002 | CA2440555A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | CA2440467A1 Ensemble-based strategy for the design of protein pharmaceuticals |
| 09/19/2002 | CA2440433A1 Cell culture system for synthesis of infectious hepatitis c virus |
| 09/19/2002 | CA2440353A1 Thiopeptide compounds |
| 09/19/2002 | CA2440345A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 09/19/2002 | CA2440208A1 Tumour targeting prodrugs activated by metallo matrixproteinases |
| 09/19/2002 | CA2440144A1 Methods for reducing fat by administration of adiponectin |
| 09/19/2002 | CA2440058A1 Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy27 |
| 09/19/2002 | CA2439897A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 09/19/2002 | CA2439735A1 Igf antagonist peptides |
| 09/19/2002 | CA2439702A1 Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof |
| 09/19/2002 | CA2439653A1 Remedies for arthritis deformans and remedies for rheumatoid arthritis |
| 09/19/2002 | CA2439637A1 Human serpin polypeptides |
| 09/19/2002 | CA2439612A1 Modulation of smooth muscle cell proliferation |
| 09/19/2002 | CA2439498A1 Somatostatin antagonists |
| 09/19/2002 | CA2439236A1 Immuno-enhancing agent |
| 09/19/2002 | CA2439063A1 Combination of nateglinide or repaglinide with at least one further antidiabetic compound |